NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

hyperopia, NWBO is in the unique position of already having approval from MHRA to treat patients under the specials, compassionate program where patients pay for their treatment. So, on the day MHRA approves DCVax-L, which longs expect, how can they deny treatment to UK patients who rush to Sawston for the treatment, even if that means adding their names to a backlog of patients? I think UK will be forced to pay for their treatment from day one, and I believe they have a program to guarantee that payment for patients between approval date and NICE setting payment amount. I can't help but think commercialization begins immediately for UK patients, with MHRA paying something to NWBO until NICE confirms the actual amount, then reembursing them the difference, if there is any.
Meanwhile, the specials program has allowed NWBO to ramp up manufacturing which is on the brink of bringing on automated manufacturing. If the Eden unit lags behind manufacturing approval, I believe they will use the manual method. I can see the compassionate program closing to foreigners and other cancer types until Eden is in place so that they can handle the UK patients.